Clinical trials
Breast Cancer Screening clinical trials
Below are recruiting breast cancer screening clinical trials, each written for real people, not researchers. We’re tracking 620 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06227117RecruitingPhase 2
Study of DV and Toripalimab before surgery for HER2-low breast cancer
This trial tests a combination of two drugs (DV and Toripalimab) with chemotherapy before surgery for a specific type of breast cancer (HER2-low, HR-negative) that has not spread too far. The goal is to see if this approach can shrink the tumor and improve outcomes.
Changsha, HunanAges 18 years+ - NCT06236269RecruitingPhase 2
Sacituzumab Govitecan for HR+/HER2- advanced breast cancer
This trial tests a drug called Sacituzumab Govitecan for people with HR+/HER2- advanced or metastatic breast cancer that has stopped responding to a CDK4/6 inhibitor. It looks at whether the drug can slow down the cancer and requires you to have a tumor biopsy.
Badalona, BarcelonaAges 18 years+ - NCT06247449Recruiting
MRI screening for brain metastases in aggressive breast cancer
This trial uses an MRI scan to look for early signs of breast cancer spreading to the brain in people with certain aggressive breast cancer types (triple-negative or HER2-positive) that are stage IIb or III. The goal is to find and treat brain metastases earlier, before they cause symptoms.
Toronto, OntarioAges 18 years+ - NCT06259929RecruitingPhase 2
Neoadjuvant abemaciclib and giredestrant for early breast cancer
This trial tests a combination of two oral medications (abemaciclib and giredestrant) given before surgery to women with a common type of early breast cancer (hormone receptor-positive, HER2-negative). The goal is to see if this treatment can shrink the tumor before surgery.
Catania, CataniaAges 18 years+ - NCT06268405Recruiting
PET scan and blood test for high-risk breast screening
This study tests a new PET scan machine for the breast (positron emission mammography) along with a blood test called a liquid biopsy for women who need a biopsy after a high-risk breast screening. It may help find cancer more accurately and less invasively.
Toronto, OntarioAges 18 years+ - NCT06268652RecruitingPhase 3
Personalized treatment guided by lab-grown tumor samples for advanced breast cancer
This trial tests whether using a personalized approach—growing your tumor cells in the lab to find the best treatment—can work better than standard treatments chosen by your doctor. It is for people with advanced breast cancer that has stopped responding to at least two previous treatments.
Guangzhou, None SelectedAges 18 years+ - NCT06276868RecruitingPhase 2
Darsilide plus hormone therapy and double antibody for breast cancer
This trial tests if adding a new drug (darsilide) to standard hormone therapy and two antibodies (trastuzumab and pertuzumab) before surgery can improve outcomes for women with HR-positive, HER2-positive breast cancer that hasn't spread.
Henan, HenanAges 18–70 - NCT06305312Recruiting
Community help for women with abnormal mammogram results
This study connects people who had an abnormal mammogram result with community resources to address social needs like food, housing, or transportation. The goal is to reduce barriers to follow-up care and promote health equity.
Salt Lake City, UtahAges 18 years+ - NCT06313983RecruitingPhase 3
Study of hemay022 plus hormone therapy for advanced breast cancer
This trial tests a new targeted drug (hemay022) combined with an aromatase inhibitor (a type of hormone therapy) for people with advanced breast cancer that is both hormone-receptor-positive and HER2-positive. It may be an option if you've already tried trastuzumab or a similar treatment and it stopped working.
BeijingAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT06331169RecruitingPhase 1
Testing anlotinib plus trastuzumab deruxtecan for advanced breast cancer
This trial tests a combination of two targeted drugs — anlotinib (which cuts off a tumor's blood supply) and trastuzumab deruxtecan (which attacks HER2-low cancer cells) — for advanced breast cancer that has stopped responding to previous treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06348134RecruitingPhase 2
Anti-HER2 Therapy Before and After Surgery for HER2-Positive Breast Cancer
This trial tests a targeted therapy (anti-HER2) given before and after surgery for Nigerian women with HER2-positive breast cancer. It aims to see if this treatment helps shrink tumors and improve outcomes.
Ikeja, LagosAges 18 years+ - NCT06383026Recruiting
Hormone Therapy Breast Cancer Screening Pilot
This pilot study tests a new way to screen for breast cancer in people who have taken hormone therapy (like estrogen, progesterone, or testosterone). It aims to include both men and women between 40 and 75, and younger people (30-39) with a family history of breast cancer.
Milwaukee, WisconsinAges 30–75 - NCT06439693RecruitingPhase 2
Sequential therapy for newly diagnosed HER2+ breast cancer that has spread
This trial tests a sequence of targeted therapies for people newly diagnosed with HER2-positive breast cancer that has spread to other parts of the body. The goal is to find a treatment plan that can potentially cure the cancer.
Boston, MassachusettsAges 18 years+ - NCT06446882Recruiting
HER2DX test to guide treatment for early HER2+ breast cancer
This trial tests whether a new test (HER2DX) can help doctors choose the best treatment combination for HER2-positive breast cancer before surgery. It's for people whose cancer hasn't spread and who haven't started therapy yet.
GrazAges 18 years+ - NCT06452706RecruitingPhase 2
Study of TQB2102 for HER2-negative breast cancer that has spread
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
Bozhou, AnhuiAges 18–75 - NCT06476119Recruiting
Optimizing treatment for low stage triple-negative breast cancer with high immune cells
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
Sittard-Geleen, LimburgAges 18 years+ - NCT06488378RecruitingPhase 1
Axatilimab and olaparib for BRCA/PALB2-mutated breast cancer
This trial tests combining two drugs – axatilimab and olaparib (a PARP inhibitor) – for people with advanced HER2-negative breast cancer that carries a BRCA or PALB2 gene mutation. The goal is to see if this new combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06502691RecruitingPhase 1/Phase 2
New imaging test to measure PARP in metastatic breast cancer
This trial tests a new imaging scan called [18F]FTT PET that may show how much of a protein called PARP is in your tumors. This could help doctors decide if a PARP inhibitor (a type of targeted therapy) is right for you. You may be able to join if you have metastatic breast cancer and are already planning to take a PARP inhibitor.
Seattle, WashingtonAges 18 years+ - NCT06508216RecruitingPhase 1/Phase 2
New drug combo for early relapsed triple-negative breast cancer
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
VillejuifAges 18 years+ - NCT06545682RecruitingPhase 1
Study of alpelisib and pembrolizumab for advanced breast cancer or melanoma
This trial tests a combination of two drugs, alpelisib and pembrolizumab, for people with advanced triple-negative breast cancer or melanoma that has spread. The goal is to see if the combination can help shrink tumors, including those that have spread to the brain.
Houston, TexasAges 18 years+ - NCT06547840RecruitingPhase 1
Study of MOv18 IgE for ovarian, endometrial, and breast cancers with a specific marker
This trial tests a new antibody treatment called MOv18 IgE for patients with advanced ovarian, endometrial, or triple-negative breast cancers that have a protein called folate receptor alpha (FRα) on their tumor cells. The goal is to see if the treatment is safe and effective.
BristolAges 18 years+ - NCT06568692RecruitingPhase 2
Study of PCS6422 with capecitabine for advanced breast cancer
This trial tests a new drug combination (PCS6422 plus capecitabine) for people with advanced or metastatic breast cancer that has not responded to other treatments. The goal is to see if adding PCS6422 can make the chemotherapy work better.
Tucson, ArizonaAges 18 years+ - NCT06577987RecruitingPhase 1
Study of CID-078 for advanced solid tumors
This trial tests an experimental drug called CID-078 for people with advanced solid tumors that have stopped responding to other treatments. It aims to find the right dose and see if the drug can shrink tumors.
Sarasota, FloridaAges 12 years+
Hear when a new Breast Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer screening?
- Yes. Clin2 currently lists 620 recruiting breast cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.